SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012236
Filing Date
2024-08-14
Accepted
2024-08-14 16:15:42
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avbp-20240630x10q.htm   iXBRL 10-Q 1204751
2 EX-10.1 avbp-20240630xex10d1.htm EX-10.1 435323
3 EX-31.1 avbp-20240630xex31d1.htm EX-31.1 15729
4 EX-31.2 avbp-20240630xex31d2.htm EX-31.2 15723
5 EX-32.1 avbp-20240630xex32d1.htm EX-32.1 7770
6 EX-32.2 avbp-20240630xex32d2.htm EX-32.2 7764
  Complete submission text file 0001558370-24-012236.txt   5669032

Data Files

Seq Description Document Type Size
7 EX-101.SCH avbp-20240630.xsd EX-101.SCH 32479
8 EX-101.CAL avbp-20240630_cal.xml EX-101.CAL 28053
9 EX-101.DEF avbp-20240630_def.xml EX-101.DEF 124479
10 EX-101.LAB avbp-20240630_lab.xml EX-101.LAB 310552
11 EX-101.PRE avbp-20240630_pre.xml EX-101.PRE 244998
65 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20240630x10q_htm.xml XML 844164
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41929 | Film No.: 241208059
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)